From MD Anderson: Smoking, p53 Mutation, and Lung Cancer

Mol Cancer Res. 2014 Jan;12(1):3-13. doi: 10.1158/1541-7786.MCR-13-0539.

Smoking, p53 Mutation, and Lung Cancer.

Gibbons DL, Byers LA, Kurie JM.

Author information

• University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 0432, Houston, Texas 77030. dlgibbon@mdanderson.org.

Abstract

This issue marks the 50th anniversary of the release of the U.S. Surgeon General's Report on Smoking and Health. Perhaps no other singular event has done more to highlight the effects of smoking on the development of cancer. Tobacco exposure is the leading cause of cancers involving the oral cavity, conductive airways, and the lung. Owing to the many carcinogens in tobacco smoke, smoking-related malignancies have a high genome-wide burden of mutations, including in the gene encoding for p53. The p53 protein is the most frequently mutated tumor suppressor in cancer, responsible for a range of critical cellular functions that are compromised by the presence of a mutation. Herein, we review the epidemiologic connection between tobacco exposure and cancer, the molecular basis of p53 mutation in lung cancer, and the normal molecular and cellular roles of p53 that are abrogated during lung tumor development and progression as defined by in vitro and in vivo studies. We also consider the therapeutic potential of targeting mutant p53 in a clinical setting based upon the cellular role of mutant p53 and data from genetic murine models.